FlexGen

Illumina has launched its TruSeq Amplicon — Cancer Panel, which targets 35 kilobases of mutational hotspots from 48 known cancer genes with 212 amplicons.

FlexGen of the Netherlands said last week that China's BGI and Leiden University Medical Center will use its target enrichment technology to validate variants for the Genome of the Netherlands, or GoNL, project.

FlexGen has launched a set of target enrichment products in its FleXelect product line. The products include a whole-exome enrichment kit as well as several targeted gene panels, including a cancer risk panel, hereditary diseases panel, and a BRCA screening kit.

The firm will use the undisclosed amount to optimize the protocols for its genomic-selection application and to start building a sales and marketing force that "will become more visible in the second half of this year," CEO Fred Dom said.

The firm raised several million euros in funding, which it will use to speed up development and global commercialization of its FlexArrayer for producing custom microarrays.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.